PME-1, an extended-spectrum β-lactamase identified in Pseudomonas aeruginosa

Guo Bao Tian, Jennifer M. Adams-Haduch, Tatiana Bogdanovich, Hong Ning Wang, Yohei Doi

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

A novel extended-spectrum β-lactamase (ESBL) was identified in a Pseudomonas aeruginosa clinical isolate obtained from a patient admitted to a hospital in Pennsylvania in 2008. The patient had a prolonged hospitalization in a hospital in Dubai, United Arab Emirates, before being transferred to the United States. The novel ESBL, designated PME-1 (Pseudomonas aeruginosa ESBL 1), is a molecular class A, Bush-Jacoby-Medeiros group 2be enzyme and shared 50, 43, and 41% amino acid identity with the L2 β-lactamase of Stenotrophomonas maltophilia, CTX-M-9, and KPC-2, respectively. PME-1 conferred clinically relevant resistance to ceftazidime, cefotaxime, cefepime, and aztreonam in P. aeruginosa PAO1 but not to carbapenems. Purified PME-1 showed good hydrolytic activity against ceftazidime, cefotaxime, and aztreonam, while activity against carbapenems and cefepime could not be measured. PME-1 was inhibited well by β-lactamase inhibitors, including clavulanic acid, sulbactam, and tazobactam. The blaPME-1 gene was carried by an approximately 9-kb plasmid and flanked by tandem ISCR24 elements.

Original languageEnglish
Pages (from-to)2710-2713
Number of pages4
JournalAntimicrobial agents and chemotherapy
Volume55
Issue number6
DOIs
Publication statusPublished - 01-06-2011

Fingerprint

Pseudomonas aeruginosa
Aztreonam
Carbapenems
Ceftazidime
Cefotaxime
United Arab Emirates
Stenotrophomonas maltophilia
Sulbactam
Clavulanic Acid
Hospitalization
Plasmids
Amino Acids
Enzymes
Genes
cefepime

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Tian, Guo Bao ; Adams-Haduch, Jennifer M. ; Bogdanovich, Tatiana ; Wang, Hong Ning ; Doi, Yohei. / PME-1, an extended-spectrum β-lactamase identified in Pseudomonas aeruginosa. In: Antimicrobial agents and chemotherapy. 2011 ; Vol. 55, No. 6. pp. 2710-2713.
@article{2fc3f1f67c984ec686bcddb89891b048,
title = "PME-1, an extended-spectrum β-lactamase identified in Pseudomonas aeruginosa",
abstract = "A novel extended-spectrum β-lactamase (ESBL) was identified in a Pseudomonas aeruginosa clinical isolate obtained from a patient admitted to a hospital in Pennsylvania in 2008. The patient had a prolonged hospitalization in a hospital in Dubai, United Arab Emirates, before being transferred to the United States. The novel ESBL, designated PME-1 (Pseudomonas aeruginosa ESBL 1), is a molecular class A, Bush-Jacoby-Medeiros group 2be enzyme and shared 50, 43, and 41{\%} amino acid identity with the L2 β-lactamase of Stenotrophomonas maltophilia, CTX-M-9, and KPC-2, respectively. PME-1 conferred clinically relevant resistance to ceftazidime, cefotaxime, cefepime, and aztreonam in P. aeruginosa PAO1 but not to carbapenems. Purified PME-1 showed good hydrolytic activity against ceftazidime, cefotaxime, and aztreonam, while activity against carbapenems and cefepime could not be measured. PME-1 was inhibited well by β-lactamase inhibitors, including clavulanic acid, sulbactam, and tazobactam. The blaPME-1 gene was carried by an approximately 9-kb plasmid and flanked by tandem ISCR24 elements.",
author = "Tian, {Guo Bao} and Adams-Haduch, {Jennifer M.} and Tatiana Bogdanovich and Wang, {Hong Ning} and Yohei Doi",
year = "2011",
month = "6",
day = "1",
doi = "10.1128/AAC.01660-10",
language = "English",
volume = "55",
pages = "2710--2713",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

PME-1, an extended-spectrum β-lactamase identified in Pseudomonas aeruginosa. / Tian, Guo Bao; Adams-Haduch, Jennifer M.; Bogdanovich, Tatiana; Wang, Hong Ning; Doi, Yohei.

In: Antimicrobial agents and chemotherapy, Vol. 55, No. 6, 01.06.2011, p. 2710-2713.

Research output: Contribution to journalArticle

TY - JOUR

T1 - PME-1, an extended-spectrum β-lactamase identified in Pseudomonas aeruginosa

AU - Tian, Guo Bao

AU - Adams-Haduch, Jennifer M.

AU - Bogdanovich, Tatiana

AU - Wang, Hong Ning

AU - Doi, Yohei

PY - 2011/6/1

Y1 - 2011/6/1

N2 - A novel extended-spectrum β-lactamase (ESBL) was identified in a Pseudomonas aeruginosa clinical isolate obtained from a patient admitted to a hospital in Pennsylvania in 2008. The patient had a prolonged hospitalization in a hospital in Dubai, United Arab Emirates, before being transferred to the United States. The novel ESBL, designated PME-1 (Pseudomonas aeruginosa ESBL 1), is a molecular class A, Bush-Jacoby-Medeiros group 2be enzyme and shared 50, 43, and 41% amino acid identity with the L2 β-lactamase of Stenotrophomonas maltophilia, CTX-M-9, and KPC-2, respectively. PME-1 conferred clinically relevant resistance to ceftazidime, cefotaxime, cefepime, and aztreonam in P. aeruginosa PAO1 but not to carbapenems. Purified PME-1 showed good hydrolytic activity against ceftazidime, cefotaxime, and aztreonam, while activity against carbapenems and cefepime could not be measured. PME-1 was inhibited well by β-lactamase inhibitors, including clavulanic acid, sulbactam, and tazobactam. The blaPME-1 gene was carried by an approximately 9-kb plasmid and flanked by tandem ISCR24 elements.

AB - A novel extended-spectrum β-lactamase (ESBL) was identified in a Pseudomonas aeruginosa clinical isolate obtained from a patient admitted to a hospital in Pennsylvania in 2008. The patient had a prolonged hospitalization in a hospital in Dubai, United Arab Emirates, before being transferred to the United States. The novel ESBL, designated PME-1 (Pseudomonas aeruginosa ESBL 1), is a molecular class A, Bush-Jacoby-Medeiros group 2be enzyme and shared 50, 43, and 41% amino acid identity with the L2 β-lactamase of Stenotrophomonas maltophilia, CTX-M-9, and KPC-2, respectively. PME-1 conferred clinically relevant resistance to ceftazidime, cefotaxime, cefepime, and aztreonam in P. aeruginosa PAO1 but not to carbapenems. Purified PME-1 showed good hydrolytic activity against ceftazidime, cefotaxime, and aztreonam, while activity against carbapenems and cefepime could not be measured. PME-1 was inhibited well by β-lactamase inhibitors, including clavulanic acid, sulbactam, and tazobactam. The blaPME-1 gene was carried by an approximately 9-kb plasmid and flanked by tandem ISCR24 elements.

UR - http://www.scopus.com/inward/record.url?scp=79956292854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956292854&partnerID=8YFLogxK

U2 - 10.1128/AAC.01660-10

DO - 10.1128/AAC.01660-10

M3 - Article

C2 - 21402845

AN - SCOPUS:79956292854

VL - 55

SP - 2710

EP - 2713

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

ER -